These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23415605)

  • 21. Pediatric systemic lupus erythematosus in Thammasat University Hospital.
    Pusongchai T; Jungthirapanich J; Khositseth S
    J Med Assoc Thai; 2010 Dec; 93 Suppl 7():S283-93. PubMed ID: 21294427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effectiveness of minimal doses of rituximab in a patient with rheumatoid arthritis.
    Bruzzese V
    Int J Immunopathol Pharmacol; 2011; 24(1):265-7. PubMed ID: 21496414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).
    Witt M; Grunke M; Proft F; Baeuerle M; Aringer M; Burmester G; Chehab G; Fiehn C; Fischer-Betz R; Fleck M; Freivogel K; Haubitz M; Kötter I; Lovric S; Metzler C; Rubberth-Roth A; Schwarting A; Specker C; Tony HP; Unger L; Wassenberg S; Dörner T; Schulze-Koops H;
    Lupus; 2013 Oct; 22(11):1142-9. PubMed ID: 24057058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.
    Payet S; Soubrier M; Perrodeau E; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Gottenberg JE; Mariette X
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1289-95. PubMed ID: 25299001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Optimizing rheumatoid arthritis treatment with rituximab--individualized patient approach].
    Novak S
    Reumatizam; 2010; 57(2):156-7. PubMed ID: 21875021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort.
    Chatzidionysiou K; van Vollenhoven RF
    Scand J Rheumatol; 2013; 42(3):190-5. PubMed ID: 23286833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study.
    Fernández-Nebro A; de la Fuente JL; Carreño L; Izquierdo MG; Tomero E; Rúa-Figueroa I; Hernández-Cruz BE; Narváez J; Ucar E; Olivé A; Zea A; Fernández-Castro M; Raya-Álvarez E; Pego-Reigosa JM; Freire M; Martínez-Taboada VM; Pérez-Venegas J; Sánchez-Atrio AI; Villa-Blanco I; Manrique-Arija S; López-Longo FJ; Carreira PE; Martínez-Pérez R; García-Vicuña R
    Lupus; 2012 Sep; 21(10):1063-76. PubMed ID: 22786985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential Benefit of Rituximab in Rhupus Patients From a Single-Center: A Series of 16 Cases.
    Rottenberg P; Brevet P; Leclercq M; Jouen F; Marie I; Lévesque H; Lequerré T; Vittecoq O
    J Clin Rheumatol; 2022 Dec; 28(8):e699-e702. PubMed ID: 35293888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical analysis of 56 patients with rhupus syndrome: manifestations and comparisons with systemic lupus erythematosus: a retrospective case-control study.
    Li J; Wu H; Huang X; Xu D; Zheng W; Zhao Y; Liu W; Zeng X
    Medicine (Baltimore); 2014 Aug; 93(10):e49. PubMed ID: 25170930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
    Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
    Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE; Guillevin L; Lambotte O; Combe B; Allanore Y; Cantagrel A; Larroche C; Soubrier M; Bouillet L; Dougados M; Fain O; Farge D; Kyndt X; Lortholary O; Masson C; Moura B; Remy P; Thomas T; Wendling D; Anaya JM; Sibilia J; Mariette X;
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
    Ezeonyeji AN; Isenberg DA
    Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab-it was the best of times, it was the worst of times.
    Isenberg DA
    Autoimmun Rev; 2012 Sep; 11(11):790-1. PubMed ID: 22349619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial.
    Haraoui B; Bokarewa M; Kallmeyer I; Bykerk VP;
    J Rheumatol; 2011 Dec; 38(12):2548-56. PubMed ID: 21965646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients.
    Tani C; D'Aniello D; Delle Sedie A; Carli L; Cagnoni M; Possemato N; Carbone M; Della Rossa A; Riente L; Baldini C; Talarico R; Caramella D; Bombardieri S; Mosca M
    Autoimmun Rev; 2013 Feb; 12(4):537-41. PubMed ID: 23063507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
    Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
    Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic vasculitis in a patient with rhupus syndrome.
    Zengin O; Onder ME; Sarica MA; Turkbeyler IH; Kimyon G; Demir ZH; Yildiz H; Kisacik B; Onat AM
    Reumatismo; 2015 Dec; 67(4):161-4. PubMed ID: 27215182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.
    Thurlings RM; Boumans M; Tekstra J; van Roon JA; Vos K; van Westing DM; van Baarsen LG; Bos C; Kirou KA; Gerlag DM; Crow MK; Bijlsma JW; Verweij CL; Tak PP
    Arthritis Rheum; 2010 Dec; 62(12):3607-14. PubMed ID: 20722020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.